Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$1.71M-$1.71MN/M vs Q1 2024 EPS Diluted-$240.07-$240.07N/M vs Q1 2024 Operating Income-$1,718,695N/M Operating Cash Flow-$1,181,714N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end